Endothelial cell injury in cardiac surgery: salicylate may be protective by reducing expression of endothelial adhesion molecules by Zünd, Gregor et al.
European Journal of Cardio-thoracic Surgery 13 (1998) 293–297
Endothelial cell injury in cardiac surgery: salicylate may be protective
by reducing expression of endothelial adhesion molecules1
Gregor Zu¨nd a,b,*, Andrea L. Dzus b, Rene´ Preˆtre a, Urs Niederha¨user a, Paul Vogt a,
Marko Turina a
a Clinic for Cardio-6ascular Surgery, Uni6ersity Hospital, Ra¨mistrasse 100, CH-8091 Zurich, Switzerland
b Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women’s Hospital, Har6ard Medical School, Boston, MA, USA
Received 29 September 1997; received in revised form 3 December 1997; accepted 9 December 1997
Abstract
Objective: Cardiac surgery with cardiopulmonary bypass induces ischemia to the heart, hypoxemia to various tissues and release
of endotoxins. The endothelial cell may suffer from hypoxia and trigger cascades of adverse reactions by activation of neutrophils
through adhesion molecules. The authors measured expression of intercellular adhesion molecule-1 (ICAM-1), during hypoxia and
normoxia and hypothesized that salicylate, which inhibits the nuclear factor-kB (NFkB), an hypoxia-dependent transmission
factor, could reduce this expression. Methods: Human umbilical vein endothelial cells were cultured and exposed to normoxia and
hypoxia in the presence of lipopolysaccharide (LPS). The endothelial cells were thereafter treated with salicylate or indomethacin
under the same conditions. The surface expression of ICAM-1 was measured by whole cell enzyme-linked immunosorbent assay
(ELISA) and the NFkB expression by Western blotting. Results: In the presence of LPS and under hypoxic conditions, the
endothelial cells produced a 300941% increased expression of ICAM-1 compared with normoxia. The addition of salicylate
(0.02–20 mM) completely inhibited the enhanced expression of ICAM-1, the addition of indomethacin at equivalent concentra-
tions did not reduce ICAM-1 expression under either condition. Conclusion: ICAM-1 expression is greatly enhanced by the
hypoxic endothelial cell in the presence of circulating endotoxin. Pre-treatment with salicylate completely abolishes the enhanced
expression. The study suggests that salicylate administered before cardiopulmonary bypass might protect the heart against
ischemic:reperfusion injuries and reduce the load of the overall inflammatory reaction. © 1998 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Cardiac surgery with cardiopulmonary bypass in-
duces ischemia to the heart, hypoxemia to various
tissues and a surge of endotoxins and cytokines
[1,10,11]. Reperfusion injury to ischemic or hypoxic has
been shown to be mediated, at least in part, by recruit-
ment of leukocytes [2]. Since endothelial cells are
anatomically located at the interface of the blood and
tissue exchange they are directly influenced by circulat-
ing mediators and therefore of special interest [3].
Migration of leukocytes across the intact endothe-
lium occurs through a concerted series of adhesion and
de-adhesion events involving a number of cell surface
adhesion proteins [4]. Previous studies have demon-
strated that short-term hypoxia or anoxia induces in-
creased adhesion of leukocytes to vascular endothelial
cells mediated by the upregulation of endothelial adhe-
sion molecules [5,6]. Intercellular adhesion molecule-1
(ICAM-1, CD54) mediates the firm adherence of leuko-
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cytes to the endothelium [4]. ICAM-1 expression is
readily induced by stimulation of cell surface receptors
by a number of inflammatory mediators, including
lipopolysaccharides (LPS) and cytokines [4]. In addi-
tion, ICAM-1 is regulated by the transcription factor
NF-kB (nuclear factor-kB) [7] which has been shown
in previous studies to be regulated by hypoxia [8].
A strategy that would inhibit the migration of leuko-
cytes across the endothelial layer would blunt the infl-
ammatory response induced by cardio-pulmonary
bypass and prevent, or at least reduce, the tissue is-
chemia-reperfusion injuries [9]. Because salicylate is in-
hibiting NF-kB, the authors hypothesized that the
administration of this drug would reduce the enhance-
ment of ICAM-1 expression. To test the hypothesis, the
authors used an in-vitro model of endothelial cell and
the authors were simulating the CPB.
2. Material and methods
2.1. Objecti6es of the study
First step, measurement of endothelial ICAM-1 ac-
tivity under hypoxic conditions after exposure to salicy-
late or indometacin. Second step, proof of the salicylate
effect by Western blotting of NFkB.
2.2. Cell culture
Human umbilical vein endothelial cells (HUVEC)
were obtained and harvested using 0.1% collagenase
(Worthington Biochemical, Freehold, NJ). Endothelial
monolayers were established, maintained and subcul-
tured with DMEM (Gibco, Grand Island, NY) contain-
ing 10% heat inactivated fetal calf serum, glucose,
pyruvate, glutamine, penicillin and streptomycin.
Confluent endothelial monolayers exhibited typical cob-
blestone appearance and expressed characteristics of
endothelial cells like the uptake of acetylated low den-
sity lipoproteins (Biomedical Technology, Stoughton,
MA). Endothelial cell passages 2–5 were used for
experiments.
2.3. Creation of hypoxic conditions
Confluent endothelial monolayers were exposed to
hypoxia as follows, growth medium was replaced with
fresh media equilibrated with hypoxic gas mixture and
cells were placed in the hypoxic chamber (Coy Labora-
tory Products, Ann Arbor, MI). This hypoxia chamber
consists of an airtight glove box with the atmosphere
continuously monitored by an oxygen analyzer inter-
faced with oxygen and nitrogen flow adaptors. Oxygen
concentrations were adjusted by oxygen and nitrogen
flow adaptors and were obtained by the balance be-
tween nitrogen, carbon dioxide (ambient 5% CO2) and
water vapor from the humidified chamber. Media pO2
and pH were measured in a Ciba-Corning 238 Blood
Gas Analyzer (Chiron Diagnostics, Norwood, MA).
2.4. Cell surface immunoassay
ICAM-1 cell surface expression was quantified using
a cell surface enzyme-linked immunosorbent assay
(ELISA). Endothelial cells were grown and assayed for
antibody binding following exposure to normoxia or
hypoxia in the presence of LPS. Endothelia were lightly
fixed with paraformaldehyde (1% w:v in phosphate
buffered saline) to preserve cell surface protein. Cells
were washed with HBSS (Sigma, St. Louis, MO),
blocked with media for 30 min at 4°C. Anti-ICAM-1
mAb (clone P2A4 obtained from the Developmental
Studies Hybridoma Bank, Iowa City IA, used as undi-
luted cell culture supernatant) was added to fixed cells
and allowed them to incubate for 2 h at 4°C. Where
indicated, mAb to MHC class I (clone W6:32 obtained
from the American Type Culture Collection, used as
1:100 diluted ascitic fluid) was used as control. After
washing with HBSS, a peroxidase conjugated sheep
anti-mouse secondary antibody (Cappel, West Chester,
PA) was added. After washing plates were developed by
addition of peroxidase substrate (2,2%-azino bis(3-ethyl-
benzthiazoline-6-sulfonic acid), 1 mM final concentra-
tion, Sigma) and read on a microtiter plate
spectrophotometer at 405 nm (Molecular Devices).
Controls consisted of media only and secondary anti-
body only.
2.5. NFkB Western blotting
HUVEC were grown to confluence on six well plates
and exposed to experimental conditions, washed, lysed
and debris was removed as described above. Proteins
were measured (DC protein assay, BioRad, Hecules,
CA). Samples (50 mg:lane) of HUVEC lysates were
separated by non-reducing SDS PAGE, transferred to
nitrocellulose and blocked overnight in blocking buffer
(250 mM NaCl, 0.02% Tween-20, 5% goat serum and
3% bovine serum albumin). Primary Ab (rabbit poly-
clonal specific for p65 subunit of NFkB, Biomol Re-
search Labs, Plymouth Meeting, PA) was added for 3
h, blots were washed and species-matched peroxidase-
conjugated secondary Ab was added. Labeled bands
from washed blots were detected by ECL. Resulting 65
kD NFkB bands were quantified from scanned images
using NIH Image software (Bethesda, MD). Such 65
kD band were specific for NFkB since preincubation of
rabbit polyclonal antibody with standard p65 antigen
(provided by Biomol as a control) resulted in a diminu-
tion of the 65 kD band by more than 70%.
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2.6. Data presentation
ELISA data were compared by one or two-factor
analyze of variance (ANOVA) or by student’s t-test.
Values are expressed as the mean and S.E.M. of n
experiments.
3. Results
Endothelial monolayers tolerated exposure to hy-
poxia well (ambient O2 as low as 1%, for up to 24 h).
No changes in morphology were observed and no evi-
dence of cell death was apparent.
3.1. Sodium salicylate normalizes hypoxia-elicited
ICAM-1 surface expression
The authors first examined the induction of ICAM-1
surface expression induced by LPS with endothelial
exposure to hypoxia and normoxia. Under hypoxic
conditions a 2-fold increase in ICAM-1 expression was
observable on HUVEC (two-way ANOVA, PB0.025
compared with normoxia) (Figs. 1 and 2). As shown in
Fig. 1, salicylate (NaSal, concentration range 0.02–20
mM) dose dependently decreased LPS-stimulated
ICAM-1 on HUVEC under conditions of both hypoxia
(one-way ANOVA, PB0.01) and normoxia (one-way
ANOVA, PB0.05). Endothelial exposure to in-
domethacin (concentration range 0.02–20 mM) at
equivalent concentrations did not influence ICAM-1
expression under either condition (Fig. 2, Pnot sig-
nificant for both). In comparison sodium salicylate but
Fig. 2. ICAM-1 expression of endothelial cells exposed to hypoxia
(ambient O2 1%, closed symbols) or normoxia (ambient O2 21%, open
symbols) in the presence of LPS (100 ng:ml) with and without
indicated concentrations indomethacin (INDO) for 18 h.
not indomethacin is inhibiting the expression of LPS
stimulated HUVEC of ICAM-1 under hypoxic
conditions.
3.2. Mechanism of hypoxia elicited upregulation of
ICAM-1
The authors demonstrated that hypoxia alone in-
creases cellular content of the p65 subunit of NFkB.
Increased periods of hypoxia alone resulted in a graded
increase in p65 content over normoxic controls (Fig. 3).
The concentrations of NaSal (2 and 20mM) determined
to be effective for decreasing ICAM-1 expression also
resulted in decreased endothelial NFkB under condi-
tions of both normoxia and hypoxia (Fig. 3).
4. Discussion
Under the conditions of cardiopulmonary bypass and
clamped ascending aorta, a precondition for successful
cardiac surgery, ischemia appears to the heart, hypox-
emia to various tissues followed by the release of endo-
toxins and cytokines [1,10,11,13–15]. It has been
known for several years that the inflammatory response
to extracorporal circulation triggers underlies the occa-
sional development of postoperative organ dysfunction,
particularly of the lungs [1]. Tissue injury resulting from
reperfusion of hypoxic tissue has been shown to be
mediated, at least in part by recruitment of leukocytes
[2]. Furthermore, such recruitment of leukocytes in-
volves a concerted series of adhesion and de-adhesion
event of leukocytes and vascular endothelium [4]. An
Fig. 1. ICAM-1 expression of endothelial cells exposed to hypoxia
(ambient O2 1%, closed symbols) or normoxia (ambient O2 21%, open
symbols) in the presence of LPS (100 ng:ml) with and without
indicated concentrations of sodium salicylate (NaS) for 18 h.
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important adhesion molecule in this cascade is ICAM-
1. As shown in previous studies, ICAM-1 is upregu-
lated under the conditions of hypoxia and the influence
of cytokines or endotoxins [8]. These in vitro conditions
are even by part comparable to cardiac surgery and
extracorporal circulation and in-deed, ICAM-1 is up-
regulated in patients undergoing cardiac surgery [12].
These findings suggest that future strategies of myocar-
dial protection must not be limited to interventions
targeted at the heart itself but should also encompass
those designed to blunt the inflammatory response to
cardiopulmonary bypass. Thus the authors hypothe-
sized that the enhancement of ICAM-1 under the con-
ditions of hypoxia and LPS may be prevented by the
administration of drugs like salicylate or indomethacin
in a cardio-pulmonary bypass model.
There are different ways to protect the leukocyte-en-
dothelial interactions of the ischemia-reperfusion in-
jury. Therapeutical interventions can be categorized as
those targeted at inactivating the triggers of the re-
sponse and those targeted at inactivating the effectors
of the response. The former category primarily encom-
passes drugs or devices designed to reduce cytokine and
endotoxin release such as heparin-coated extracorporal
circuits or glucocorticoids [16–20]. The second category
of interventions includes drugs or devices to attenuate
the effects of adhesion molecules. As the authors have
shown in the result part under the condition of hypoxia
NFkB was increased. The addition of sodium salicy-
late, but not indomethacin, diminished augmentation of
both ICAM-1 expression and cellular content of
NFkB. Such observations are consistent with a previ-
ous report indicating that sodium salicylate can inhibit
induction through NFkB [28]. A contribution of cy-
clooygenase in this context could be excluded by the
addition of indomethcin which had no effect to the
expression of ICAM-1 under hypoxic conditions. The
adhesion molecules, whether expressed on leukocytes or
endothelial cells can be blocked by monoclonal anti-
bodies. This approach has been examined in various
animal models of myocardial ischemia, including a
surgically relevant preparation of heterotopic rabbit
heart transplantation and an isolated blood-perfused
swine-heart model subjected to 6 h of cold cardioplegic
ischemia [21,22]. None of these genetically engineered
compounds is clinically available yet. Alternative thera-
pies that can interfere with adhesion molecules and
have been approved for human use are being consid-
ered. Both glucocorticoid and adenosine-regulating
agent acadesine have been shown to decrease CD11b:
CD18 upregulation in patients undergoing open-heart
procedures [23,24]. Furthermore, low-dose aprotinin
has been reported to have a similar anti-inflammatory
effect to that of methylprednisolon in decreasing the
bypass-induced release of TNF-a and neutrophil CD
11b upregulation [25]. A possible more effective ap-
proach for limiting the effects of neutrophil interactions
to vascular endothelium might be the elimination of
themselves by sequestering them into appropriate
filters. A recent Japanese study has shown that leuko-
cyte and platelet depletion with a blood cell separator
reduces postoperative respiratory dysfunction [26]. At
the institution the efficiency of such a device was tested
and leukocyte filtration failed to improve postoperative
lung function [27].
The results suggest that the addition of salicylate to
the cardio-pulmonary bypass model completely inhib-
ited the enhanced expression of ICAM-1 by blocking
the hypoxia dependent NFkB transmission factor, the
addition of indomethacin at equivalent concentrations
did not influence ICAM-1 expression under either con-
dition. Thus, this study suggests that salicylate adminis-
tered before cardiopulmonary bypass might protect the
heart against ischemic:reperfusion injuries and reduce
the load of the overall inflammatory reaction.
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